Gritstone Oncology (NASDAQ:GRTS)‘s stock had its “buy” rating reaffirmed by investment analysts at Cowen in a research note issued to investors on Monday, AnalystRatings.com reports.
A number of other analysts have also weighed in on the company. Zacks Investment Research lowered Gritstone Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Gritstone Oncology in a research note on Monday, April 1st. Berenberg Bank assumed coverage on Gritstone Oncology in a research note on Wednesday, March 27th. They issued a “buy” rating on the stock. Finally, Raymond James assumed coverage on Gritstone Oncology in a research note on Thursday, March 14th. They issued an “outperform” rating and a $20.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $22.20.
GRTS stock opened at $11.14 on Monday. Gritstone Oncology has a twelve month low of $9.66 and a twelve month high of $32.90.
A number of hedge funds have recently added to or reduced their stakes in GRTS. Citigroup Inc. purchased a new stake in Gritstone Oncology in the fourth quarter worth $28,000. Strs Ohio purchased a new position in shares of Gritstone Oncology during the fourth quarter valued at $29,000. New York State Common Retirement Fund purchased a new position in shares of Gritstone Oncology during the first quarter valued at $53,000. American International Group Inc. purchased a new position in shares of Gritstone Oncology during the fourth quarter valued at $70,000. Finally, Marshall Wace North America L.P. purchased a new position in shares of Gritstone Oncology during the first quarter valued at $84,000. Institutional investors and hedge funds own 59.60% of the company’s stock.
About Gritstone Oncology
Gritstone Oncology Inc, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
Featured Article: What are catch-up contributions?
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.